The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.9M data for 1.2M Compounds and 9.3K Targets. Of those, 1,352K data for 627K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

25 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Rational design and synthesis of 1,5-disubstituted tetrazoles as potent inhibitors of the MDM2-p53 interaction.EBI
Jagiellonian University
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.EBI
Novartis Institutes For Biomedical Research
Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.EBI
Amgen
Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interaction.EBI
Amgen
The central valine concept provides an entry in a new class of non peptide inhibitors of the p53-MDM2 interaction.EBI
Novartis Institutes For Biomedical Research
Synthesis of cell-permeable stapled peptide dual inhibitors of the p53-Mdm2/Mdmx interactions via photoinduced cycloaddition.EBI
State University of New York
Functional profiling of p53-binding sites in Hdm2 and Hdmx using a genetic selection system.EBI
Purdue University
Recent Progress and Clinical Development of Inhibitors that Block MDM4/p53 Protein-Protein Interactions.EBI
University of Chinese Academy of Sciences
Structure-Based Discovery of MDM2/4 Dual Inhibitors that Exert Antitumor Activities against MDM4-Overexpressing Cancer Cells.EBI
Shanghai Institute of Materia Medica
Discovery of MDM2-p53 and MDM4-p53 protein-protein interactions small molecule dual inhibitors.EBI
Universidade De Lisboa
Rational Design of Right-Handed Heterogeneous Peptidomimetics as Inhibitors of Protein-Protein Interactions.EBI
University of South Florida
Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction.EBI
University of Groningen
The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy.EBI
Sichuan University
?-Helix-Mimicking Sulfono-?-AApeptide Inhibitors for p53-MDM2/MDMX Protein-Protein Interactions.EBI
University of South Florida
2,30-Bis(10H-indole) heterocycles: New p53/MDM2/MDMX antagonists.EBI
University of Groningen
Simultaneous Targeting of RGD-Integrins and Dual Murine Double Minute Proteins in Glioblastoma Multiforme.EBI
Universit£
1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers.EBI
Jagiellonian University
d-Amino acid mutation of PMI as potent dual peptide inhibitors of p53-MDM2/MDMX interactions.EBI
University of Maryland
Computer-Aided Identification and Lead Optimization of Dual Murine Double Minute 2 and 4 Binders: Structure-Activity Relationship Studies and Pharmacological Activity.EBI
Universit£
N-acylpolyamine inhibitors of HDM2 and HDMX binding to p53.BDB
Nih